About FasT Biopharma
FasT Biopharma is a company based in Watlington (United Kingdom) founded in 2016 by David Blakey. FasT Biopharma has raised $255.66 thousand across 1 funding round from investors including BioCity. The company has 2 employees as of February 28, 2022. FasT Biopharma offers products and services including FasL Blocking Therapy. FasT Biopharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Watlington, United Kingdom
- Employees 2 as on 28 Feb, 2022
- Founders David Blakey
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Fast Biopharma Ltd
- Date of Incorporation 02 Feb, 2016
- Jurisdiction WATLINGTON, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$255.66 K (USD)
in 1 rounds
-
Latest Funding Round
$255.66 K (USD), Seed
Jun 14, 2016
- Investors
-
Employee Count
2
as on Feb 28, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of FasT Biopharma
FasT Biopharma offers a comprehensive portfolio of products and services, including FasL Blocking Therapy.
Therapy to prevent cell death in diseases like cancer and blindness
People of FasT Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of FasT Biopharma
FasT Biopharma has successfully raised a total of $255.66K through 1 strategic funding round. The most recent funding activity was a Seed round of $255.66 thousand completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in FasT Biopharma
FasT Biopharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include BioCity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Science focused startup accelerator and incubator
|
Locked | Locked | Locked |
Investor details for FasT Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by FasT Biopharma
Investment portfolio details for FasT Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - FasT Biopharma
Detailed financials for FasT Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fast Biopharma Comparisons
Peer comparison for FasT Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of FasT Biopharma
FasT Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of FasT Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fast Biopharma
Complete news archive for FasT Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about FasT Biopharma
FasT Biopharma was founded in 2016.
FasT Biopharma is headquartered in Watlington, United Kingdom. It is registered at Watlington, Oxfordshire, United Kingdom.
Peter Davis is the current CEO of FasT Biopharma.
FasT Biopharma is a funded company, having raised a total of $255.66K across 1 funding round to date.
As of Feb 28, 2022, the latest employee count at FasT Biopharma is 2.
FasT Biopharma was founded in 2016 and is based in Watlington, United Kingdom. Focus is placed on the biopharmaceutical sector, specifically immuno-oncology. An optimized antibody is developed as the flagship product, FBP002, which remains in the pre-clinical stage. Inhibitory mechanisms are targeted to stimulate immune responses against tumors, with effects on tumor-infiltrating effector cells and reductions in tumor Tregs observed.
FasT Biopharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
FasT Biopharma offers FasL Blocking Therapy.
FasT Biopharma has 1 investor. Key investors include BioCity.
The valuation of FasT Biopharma is $614.26K as of Jun 2016.